OVISTA is a pre-clinical platform, currently focused on Alzheimer's disease and frontotemporal dementia (FTD), built on a hardware-agnostic, local-first architecture. We'd rather state our stage plainly than round it up.
The core oculomotor protocol — task structure, timing, and the metrics behind the risk band — is designed and grounded in the published literature, including the standardized antisaccade paradigm this field is built on.
CompleteThe underlying platform is built to run locally for timing precision, and to work across different eye-tracking hardware rather than being locked to a single device.
CompleteThe next phase is building OVISTA's own age- and sex-adjusted normative reference data — the foundation the Green/Amber/Red risk band is calibrated against. This is the phase we're in now.
In ProgressOnce normative data collection is underway, the next step is validating OVISTA's performance in real clinical settings, alongside the specialist assessments it's designed to support.
PlannedOVISTA is not yet cleared by any regulatory body. Pursuing the appropriate regulatory pathway follows clinical validation — we're not there yet, and we won't claim otherwise before we are.
PlannedOVISTA is currently in pre-clinical development. Our oculomotor protocols are literature-grounded and undergoing pilot validation; they are not yet cleared as a diagnostic device by any regulatory body. We publish this stage honestly because we think it matters as much as the science itself.
Whether you're a clinician, researcher, or investor, we're happy to talk through exactly where things stand.